Last reviewed · How we verify
PARP Inhibitor BGB-290 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PARP Inhibitor BGB-290 (PARP Inhibitor BGB-290) — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PARP Inhibitor BGB-290 TARGET | PARP Inhibitor BGB-290 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PARP Inhibitor BGB-290 CI watch — RSS
- PARP Inhibitor BGB-290 CI watch — Atom
- PARP Inhibitor BGB-290 CI watch — JSON
- PARP Inhibitor BGB-290 alone — RSS
Cite this brief
Drug Landscape (2026). PARP Inhibitor BGB-290 — Competitive Intelligence Brief. https://druglandscape.com/ci/parp-inhibitor-bgb-290. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab